Edgewise Therapeutics, Inc. (EWTX)
NASDAQ: EWTX · Real-Time Price · USD
35.32
-0.26 (-0.73%)
May 8, 2026, 4:00 PM EDT - Market closed
Edgewise Therapeutics Employees
Edgewise Therapeutics had 146 employees as of December 31, 2025. The number of employees increased by 36 or 32.73% compared to the previous year.
Employees
146
Change
36
Growth
32.73%
Revenue / Employee
n/a
Profits / Employee
-$1,205,548
Market Cap
3.80B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 146 | 36 | 32.73% |
| Sep 30, 2025 | 136 | 28 | 25.93% |
| Jun 30, 2025 | 126 | 29 | 29.90% |
| Mar 31, 2025 | 117 | 25 | 27.17% |
| Dec 31, 2024 | 110 | 22 | 25.00% |
| Sep 30, 2024 | 108 | 28 | 35.00% |
| Jun 30, 2024 | 97 | 23 | 31.08% |
| Mar 31, 2024 | 92 | 25 | 37.31% |
| Dec 31, 2023 | 88 | 29 | 49.15% |
| Sep 30, 2023 | 80 | 30 | 60.00% |
| Jun 30, 2023 | 74 | 32 | 76.19% |
| Mar 31, 2023 | 67 | 29 | 76.32% |
| Dec 31, 2022 | 59 | 28 | 90.32% |
| Sep 30, 2022 | 50 | 20 | 66.67% |
| Jun 30, 2022 | 42 | 16 | 61.54% |
| Mar 31, 2022 | 38 | 16 | 72.73% |
| Dec 31, 2021 | 31 | 12 | 63.16% |
| Sep 30, 2021 | 30 | 11 | 57.89% |
| Jun 30, 2021 | 26 | - | - |
| Mar 31, 2021 | 22 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Telix Pharmaceuticals | 1,184 |
| ACADIA Pharmaceuticals | 798 |
| Crinetics Pharmaceuticals | 594 |
| Travere Therapeutics | 497 |
| Catalyst Pharmaceuticals | 182 |
| Tango Therapeutics | 137 |
| NewAmsterdam Pharma Company | 100 |
| Oruka Therapeutics | 68 |
EWTX News
- 2 days ago - Edgewise Therapeutics reports Q1 EPS (46c), consensus (49c) - TheFly
- 2 days ago - Edgewise Therapeutics Reports First Quarter 2026 Financial Results and Advances Clinical Programs in Muscular Dystrophy and Cardiovascular Indications - PRNewsWire
- 2 days ago - Edgewise Therapeutics price target raised to $52 from $46 at Truist - TheFly
- 3 days ago - Edgewise Therapeutics rises 18.1% - TheFly
- 3 days ago - Cytokinetics Phase 3 data bodes well for Edgewise, says Raymond James - TheFly
- 4 days ago - Edgewise Therapeutics rises 23.3% - TheFly
- 5 days ago - Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules - PRNewsWire
- 7 weeks ago - JPMorgan ups Edgewise target, adds to Analyst Focus List - TheFly